A Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung Cancer

Locally Advanced or Metastatic NSCLC Clinical Trial

Official title:
A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of WJ13405 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung Cancer

Status Recruiting

Clinical Trial Summary

This is an open-label phase I/II preliminary study, including dose escalation, dose expansion, and efficacy expansion, to evaluate drug safety, tolerability, PK, and efficacy. The dose escalation study evaluates the IMP's safety, tolerability, and PK in patients with locally advanced or metastatic NSCLC who have experienced disease progression after third-generation EGFR-TKI therapy. The dose expansion study, after 2-3 dose levels are selected based on dose escalation results, further investigates the IMP's safety, tolerability, and PK, explores preliminary efficacy, and determines RP2D in patients with locally advanced or metastatic NSCLC harboring EGFR C797X mutation. The efficacy expansion study evaluates the IMP's safety and efficacy in patients with locally advanced or metastatic NSCLC harboring EGFR C797X mutation.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Carcinoma, Non-Small-Cell Lung
Locally Advanced or Metastatic NSCLC

Clinical Trial Details

NCT number	NCT05662670
Study type	Interventional
Source	Suzhou Junjing BioSciences Co., Ltd.
Contact	Yongdong Zhang
Phone	+86 18042483763
Email	yongdong_zhang@junshipharma.com
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	October 11, 2022
Completion date	September 1, 2026

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03037086` - Asia PDL1 Study Among NSCLC Patients	N/A
Active, not recruiting	`NCT03274479` - PBF-1129 in Patients With NSCLC	Phase 1
Recruiting	`NCT03502850` - Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer	Phase 1/Phase 2
Not yet recruiting	`NCT05990127` - A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer	Phase 3
Active, not recruiting	`NCT03969823` - Whole Genomic Landscape of Advanced EGFR-mutant NSCLC	N/A
Completed	`NCT04207775` - Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy
Completed	`NCT05631678` - Drug-drug Interaction Study Beteewn ASK120067 and Rifampicin or Itraconazole	Phase 1
Recruiting	`NCT04143607` - ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC	Phase 3
Completed	`NCT03414814` - Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation	Phase 2
Completed	`NCT04360915` - Assessing the Pharmacokinetics Effects of Food on ASK120067 in Single Oral Administration in Chinese Healthy Subjects	Phase 1